Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in the United States, Australia, New Zealand, and internationally.
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has PolyNovo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PNV's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: PNV exceeded the Australian Medical Equipment industry which returned -1.7% over the past year.
Return vs Market: PNV exceeded the Australian Market which returned -22.8% over the past year.
Price Volatility Vs. Market
How volatile is PolyNovo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StIntroducing PolyNovo (ASX:PNV), The Stock That Rocketed 1660% In The Last Five Years
3 weeks ago | Simply Wall StIndependent Non-Executive Chairman David Williams Just Bought Shares In PolyNovo Limited (ASX:PNV)
1 month ago | Simply Wall StWhat Percentage Of PolyNovo Limited (ASX:PNV) Shares Do Insiders Own?
Is PolyNovo undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PNV (A$1.54) is trading below our estimate of fair value (A$5.28)
Significantly Below Fair Value: PNV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PNV is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: PNV is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PNV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PNV is overvalued based on its PB Ratio (41.5x) compared to the AU Medical Equipment industry average (3.2x).
How is PolyNovo forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PNV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: PNV is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PNV's is expected to become profitable in the next 3 years.
Revenue vs Market: PNV's revenue (40.3% per year) is forecast to grow faster than the Australian market (4.2% per year).
High Growth Revenue: PNV's revenue (40.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PNV's Return on Equity is forecast to be very high in 3 years time (57.1%).
How has PolyNovo performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PNV is currently unprofitable.
Growing Profit Margin: PNV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PNV is unprofitable, and losses have increased over the past 5 years at a rate of -14.6% per year.
Accelerating Growth: Unable to compare PNV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PNV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).
Return on Equity
High ROE: PNV has a negative Return on Equity (-15.05%), as it is currently unprofitable.
How is PolyNovo's financial position?
Financial Position Analysis
Short Term Liabilities: PNV's short term assets (A$17.3M) exceed its short term liabilities (A$2.8M).
Long Term Liabilities: PNV's short term assets (A$17.3M) exceed its long term liabilities (A$2.3M).
Debt to Equity History and Analysis
Debt Level: PNV is debt free.
Reducing Debt: PNV has not had any debt for past 5 years.
Inventory Level: PNV has a high level of physical assets or inventory.
Debt Coverage by Assets: PNV's debt is not covered by short term assets (assets are -3.8988774363255E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PNV has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PNV has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is PolyNovo's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PNV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PNV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PNV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PNV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PNV's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Paul Brennan, MBA, BSc (Nursing), RN, RM has been the Chief Executive Officer of Polynovo Limited since February 13, 2015. Mr. Brennan has been the Marketing Director Australia and New Zealand and Sale ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD193.74K) is below average for companies of similar size in the Australian market ($USD1.07M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||5.08yrs||AU$315.87k||1.82% A$18.5m|
|CFO & Company Secretary||1.25yrs||AU$259.30k||no data|
|Director of Operations||no data||no data||no data|
|Marketing & Distributor Manager||no data||no data||no data|
|HR Manager||no data||no data||no data|
|Principal Scientist||no data||AU$145.12k||no data|
|Senior Vice President of Americas||0.50yr||no data||no data|
Experienced Management: PNV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Non-Executive Director||0.42yr||no data||no data|
|Non-Executive Independent Director||10.08yrs||AU$56.78k||0.55% A$5.6m|
|Non-Executive Director||5.83yrs||AU$56.78k||0.19% A$2.0m|
|Independent Non-Executive Chairman||6yrs||AU$89.63k||2.71% A$27.6m|
|Non-Executive Independent Director||5.83yrs||AU$56.78k||0.23% A$2.4m|
|Non-Executive Director||7.58yrs||AU$122.41k||0.19% A$1.9m|
|Independent Non-Executive Director||4.17yrs||AU$56.78k||0.20% A$2.1m|
Experienced Board: PNV's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PNV insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PolyNovo Limited's company bio, employee growth, exchange listings and data sources
- Name: PolyNovo Limited
- Ticker: PNV
- Exchange: ASX
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$1.018b
- Shares outstanding: 661.09m
- Website: https://www.polynovo.com.au
Number of Employees
- PolyNovo Limited
- 320 Lorimer Street
- Unit 2
- Port Melbourne
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CALZ.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Nov 1998|
|PNV||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Nov 1998|
|PNV||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Nov 1998|
|PNV||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Nov 1998|
|MFJ||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 1998|
Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in the United States, Australia, New Zealand, and internationally. The company focuses on the development and commercialization of medical devices using its NovoSorb technology in the treatment of burns, surgical wounds, and negative pressure wound therapy. It offers BTM (biodegradable temporising matrix), a wound dressing intended for treatment of full-thickness wounds and burns. In addition, Polynovo Limited licensed its NovoSorb to Smith & Nephew for orthopaedic applications. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited is based in Port Melbourne, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 10:32|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.